Management of Heavy Menstrual Bleeding in Adolescents

First-Line Treatment

The American Academy of Pediatrics recommends combined oral contraceptives (COCs) with 30-35 μg of ethinyl estradiol as the first-line treatment for heavy menstrual bleeding in adolescents, providing both menstrual regulation and effective contraception 1, 2
Monophasic pills containing 30-35 μg of ethinyl estradiol and a progestin such as levonorgestrel or norgestimate are recommended as initial therapy, as they decrease menstrual blood loss and cramping by inducing regular shedding of a thinner endometrium 1, 2
COCs provide additional benefits including improvement in acne and reduced risk of endometrial and ovarian cancers 1

Contraceptive Options

The contraceptive vaginal ring (NuvaRing) releases 15 μg ethinyl estradiol and 120 μg etonogestrel daily, providing comparable effectiveness to COCs with a simpler regimen (once monthly insertion) 1

Management Considerations

The Centers for Disease Control and Prevention (CDC) recommends beginning with a monophasic COC containing 30-35 μg of ethinyl estradiol, and for extended regimens, the patient takes active pills continuously for 3-4 months, followed by a 4-7 day hormone-free interval 1, 2, 3
If breakthrough bleeding occurs with extended regimens, a 3-4 day hormone-free interval can be taken, but not during the first 21 days of use and not more than once per month 3

Monitoring and Follow-up

The CDC advises that no routine follow-up visit is required, but the patient should return if she experiences side effects or concerns, and assess satisfaction with the method and any health status changes at follow-up visits 3
Blood pressure should be monitored at follow-up visits for patients on COCs 3

Management of Breakthrough Bleeding

For heavy or prolonged bleeding with COCs, the CDC recommends considering NSAIDs for 5-7 days, or if using extended regimen COCs, a hormone-free interval of 3-4 days may help (but not during first 21 days of use) 3, 4

Potential Adverse Effects and Precautions

COCs increase the risk of venous thromboembolism (VTE) three to fourfold (up to 4 per 10,000 woman-years), according to the American College of Obstetricians and Gynecologists 2

Alternative Options

Depot Medroxyprogesterone Acetate (DMPA) can be considered as a second-line treatment, and for heavy bleeding with DMPA, NSAIDs for 5-7 days may be effective 2, 3

Best Birth Control for a 17-Year-Old with Heavy Periods

First-Line Hormonal Options

If breakthrough bleeding occurs with extended regimens, a 3-4 day hormone-free interval can be taken to temporarily induce bleeding, but not during the first 21 days of use and not more than once per month, as recommended by the American Academy of Family Physicians 5
Backup contraception is needed for 7 days only if the levonorgestrel IUD is inserted more than 7 days after menses starts, according to the American Academy of Family Physicians 5

Alternative Options

Amenorrhea is common after ≥1 year of continuous use of Depot Medroxyprogesterone Acetate (DMPA), and the Centers for Disease Control and Prevention recommends enhanced counseling about expected bleeding patterns to improve continuation rates 6
The Centers for Disease Control and Prevention suggests that for heavy or prolonged bleeding with DMPA, NSAIDs for 5-7 days may be effective, and also recommends ruling out underlying gynecological problems such as STDs, pregnancy, or new pathologic uterine conditions (polyps or fibroids) 6

Critical Safety Considerations

The American Academy of Pediatrics emphasizes consistent condom use for STI protection regardless of contraceptive method chosen, and all sexually active adolescents should be encouraged to use condoms 7

Adolescent-Specific Counseling

The American Academy of Family Physicians recommends ensuring confidential discussion of family planning needs, as adolescents are significantly less likely to use family planning services without assurances of confidentiality 5
The Centers for Disease Control and Prevention suggests providing counseling about potential changes in bleeding patterns before initiating any hormonal method, and reassuring that amenorrhea with hormonal contraceptives does not require medical treatment and is generally not harmful 6

Treatment of Heavy Menstrual Bleeding in Adolescents

Benefits and Safety of Combined Oral Contraceptives

Long-term use of combined oral contraceptives (>4 years) provides significant protection against endometrial and ovarian cancers, according to the American Academy of Pediatrics 8
Combined oral contraceptives do not increase the risk of infertility or breast cancer based on observational data, as stated by the American Academy of Pediatrics 8
Extended or continuous regimens of combined oral contraceptives are particularly useful for treating anemia, severe dysmenorrhea, and heavy menstrual bleeding, with the American Academy of Pediatrics recommending this approach 8
Smoking is not a contraindication to combined oral contraceptive use in teenagers and adults younger than 35 years old, as per the American Academy of Pediatrics 8
Common transient adverse effects of combined oral contraceptives include irregular bleeding, headache, nausea, and breast pain, as reported by the American Academy of Pediatrics 8

Managing Breakthrough Bleeding and Adverse Effects

If breakthrough bleeding occurs with extended regimens, a 3-4 day hormone-free interval can be taken, but not during the first 21 days of use and not more than once per month, as recommended by the Centers for Disease Control and Prevention 9
For persistent heavy bleeding, NSAIDs for 5-7 days can be added, according to the Centers for Disease Control and Prevention 9
Before treating breakthrough bleeding, it is essential to rule out underlying conditions such as thyroid disorders, pregnancy, or new pathologic uterine conditions (polyps or fibroids), as advised by the Centers for Disease Control and Prevention 9

Counseling and Adherence

Instructing patients on what to do if pills are missed, such as taking the most recently missed pill as soon as possible, and remembering that 7 consecutive hormone pills are needed to prevent ovulation, is crucial for effective treatment, as recommended by the American Academy of Pediatrics 8
Strategies to promote daily adherence, including cell phone alarms and support from a family member, can improve treatment outcomes, according to the American Academy of Pediatrics 8

Delaying Menses with Combined Oral Contraceptives

Recommended Approach

The American Academy of Family Physicians recommends continuing active combined oral contraceptive pills without the hormone-free interval to delay menstruation, by skipping the placebo pills and immediately starting a new pack of active pills 10
Patients can skip the placebo pills for 3-4 consecutive days to temporarily induce bleeding if needed, but this should not be done during the first 21 days of use and not more than once per month, as suggested by the American family physician 10

Managing Breakthrough Bleeding

The Centers for Disease Control and Prevention notes that unscheduled spotting or bleeding is common during the first 3-6 months of extended or continuous use and generally decreases with continued use 11
If breakthrough bleeding becomes problematic, allowing a 3-4 day hormone-free interval can temporarily induce bleeding and thin the endometrium, but avoid this during the first 21 days of continuous use, as recommended by the American family physician 10
Before treating breakthrough bleeding, it is essential to rule out underlying conditions, including pregnancy, sexually transmitted infections, medication interactions, cigarette smoking, or new pathologic uterine conditions, according to the MMWR Recommendations and Reports 11

Important Counseling Points

Patients should be counseled before initiation that unscheduled bleeding is expected in the first 3-6 months but is not harmful and decreases over time, as stated by the MMWR Recommendations and Reports 11

Backup Contraception Requirements

If starting combined hormonal contraceptives more than 5 days after menses begins, backup contraception should be used for 7 days, as recommended by the American family physician 10
When switching from another method, backup contraception for 7 days is needed only if starting more than 5 days after menses, according to the American family physician 10

Management of Heavy Menstrual Bleeding

Treatment Options

The American Heart Association recommends that high-dose oral or injectable progestin-only medications may be considered short-term for hemodynamically unstable women with uncontrolled bleeding 12
The American College of Cardiology guidelines suggest that cyclic oral medroxyprogesterone reduces menstrual blood loss by approximately 87% 12
The Centers for Disease Control and Prevention recommend that injectable depot medroxyprogesterone acetate (DMPA) 150 mg intramuscularly every 12 weeks can be used, with NSAIDs for 5-7 days if heavy bleeding occurs 13
The European Society of Cardiology states that monthly injectables containing medroxyprogesterone are contraindicated in heart failure due to fluid retention 14
The American College of Obstetricians and Gynecologists guidelines indicate that levonorgestrel IUD results in 71-95% reduction in menstrual blood loss, comparable to endometrial ablation 12
The Centers for Disease Control and Prevention recommend that backup contraception is needed only if levonorgestrel IUD is inserted >7 days after menses starts 15

Contraindications and Precautions

The European Heart Journal recommends that careful clinical judgment is required in women with cardiovascular disease, as hormonal therapy is relatively contraindicated after spontaneous coronary artery dissection 12
The European Society of Cardiology states that injectable DMPA causes fluid retention and is inappropriate for patients with heart failure 14

Medication to Delay Menstruation

Contraceptive Considerations

Neither norethindrone nor COCs used for menstrual delay should be relied upon as contraception unless the patient has been using them continuously, as stated by the American Academy of Family Physicians 16

CDC Guidelines for Managing Acute Vaginal Bleeding with Combined Oral Contraceptives

Transition to Maintenance Therapy

After bleeding is controlled with a multidose regimen, patients should switch to a standard once‑daily combined oral contraceptive (COC) and continue taking the pills for at least 21 consecutive days before any hormone‑free interval to prevent recurrent bleeding. 17, 18

Standard Cyclic COC Regimen

The recommended maintenance regimen is a monophasic COC containing 30–35 µg ethinyl estradiol taken for 21–24 days followed by a 4–7‑day hormone‑free interval. 17, 18

Contraceptive Coverage (Backup Contraception)

No backup contraception is required when COCs are initiated within the first 5 days of menstrual bleeding. 17, 18
If COCs are started more than 5 days after the onset of bleeding, a 7‑day period of backup contraception (e.g., condoms) is recommended. 17, 18

Evaluation of Breakthrough Bleeding

Before managing breakthrough bleeding, clinicians should rule out pregnancy, sexually transmitted infections, new uterine pathology (such as polyps or fibroids), and potential medication interactions. 19
Patients should be counseled that unscheduled spotting or bleeding is common during the first 3–6 months of COC use and typically improves with continued use. 19

Guidelines for Switching from Oral Medroxyprogesterone to a Levonorgestrel‑Releasing IUD in Women with Abnormal Uterine Bleeding

1. Medication Transition

Discontinue oral medroxyprogesterone acetate on the day of LNG‑IUD insertion; no tapering is required. (CDC recommendation) 20
Take the final oral medroxyprogesterone dose on the morning of the IUD insertion appointment; overlap or withdrawal bleeding is not a concern. (CDC recommendation) 20

2. IUD Selection

Choose a levonorgestrel‑releasing IUD (LNG‑IUD) as the preferred device for treating heavy menstrual bleeding; copper IUDs do not reduce bleeding and may aggravate it. (CDC recommendation) 21

3. Pregnancy Exclusion and Insertion Timing

Confirm that the patient is not pregnant using clinical criteria (e.g., negative pregnancy test when indicated and no recent unprotected intercourse). (CDC recommendation) 20
The LNG‑IUD may be inserted at any point in the menstrual cycle provided pregnancy is reasonably excluded. (CDC recommendation) 20
If insertion occurs within the first 7 days after the onset of menstrual bleeding, no backup contraception is needed. (CDC recommendation) 20
Schedule insertion ideally within the first 7 days of the cycle to avoid the need for backup contraception. (CDC recommendation) 20

4. Post‑Insertion Management

Routine follow‑up visits are not required after LNG‑IUD placement; patients should return only for concerning symptoms, side‑effect discussions, or method change. (CDC recommendation) 21
Irregular spotting or light bleeding is common during the first 3–6 months after LNG‑IUD insertion and typically resolves without treatment. (CDC recommendation) 21

5. Management of Persistent Heavy Bleeding

If heavy or prolonged bleeding persists after LNG‑IUD placement, initiate NSAID therapy for 5–7 days as first‑line treatment. (CDC recommendation) 21
If NSAIDs are ineffective, consider a short course (10–20 days) of hormonal therapy such as combined oral contraceptives or estrogen. (CDC recommendation) 21

6. Follow‑Up and Device Longevity

Routine IUD string checks at every visit are unnecessary; follow‑up should be limited to specific concerns. (CDC recommendation) 21
The LNG‑IUD can remain in place for 5–8 years depending on the specific device model, after which removal or replacement is advised. (CDC recommendation) 21

Surgical Options and IUD Contraindications in Adenomyosis

Surgical Management When Medical Therapy Fails

Contraindicated Intrauterine Devices

Management of Extended‑Use Combined Oral Contraceptives

Breakthrough Bleeding in Continuous Regimens

Unscheduled spotting or bleeding occurs in most users during the first 3–6 months of extended or continuous combined oral contraceptive (COC) use; the bleeding typically diminishes with continued use and does not indicate method failure. The CDC’s MMWR Recommendations (2024) consider this a common, non‑harmful side effect. 24

Missed Pills and Risk of Ovulation

Extending the hormone‑free interval—whether intentionally or due to missed pills—is the period of highest risk for ovulation and consequent contraceptive failure. The CDC’s MMWR Recommendations (2013) advise taking any missed pill as soon as possible and using backup contraception (e.g., condoms) for 7 days if ≥ 2 consecutive pills are missed. 25

Levonorgestrel‑Releasing Intrauterine System – Evidence‑Based Guidance for Heavy Menstrual Bleeding

Efficacy Over Time

Expected Bleeding Patterns and Counseling

Management of Persistent Bleeding

Avoidance of Premature Device Removal

Diagnostic Evaluation Before Treating Persistent Bleeding

Management of Breakthrough Bleeding with Combined Oral Contraceptives in Nexplanon Users

Initiation of Combined Oral Contraceptive (COC)

Continuation of Nexplanon Implant

Missed‑Pill Management

Contraceptive Effectiveness of Nexplanon vs. COC

Progestin Choice and Non‑Oral Hormonal Options for Managing Menstrual Bleeding and Dysmenorrhea

Progestin Selection Considerations

Cost and availability should be taken into account when choosing between levonorgestrel‑containing and norgestimate‑containing monophasic combined oral contraceptives for the reduction of menstrual bleeding and cramping. 29

Depot Medroxyprogesterone Acetate (DMPA) Characteristics

Depot medroxyprogesterone acetate is administered by injection and therefore is not an oral contraceptive option for menstrual symptom control. 29

Inappropriate Use of Progestin‑Only Pills

Progestin‑only pills (mini‑pills) are not recommended for the treatment of heavy menstrual bleeding or dysmenorrhea because they primarily thicken cervical mucus rather than suppress ovulation and do not produce the endometrial thinning required for symptom relief. 29

Endometrial Recovery and Bleeding After Transition from DMPA to Combined Oral Contraceptives

Effects of Long‑Term DMPA Use

Long‑term depot medroxyprogesterone acetate (DMPA) causes marked endometrial atrophy and disrupts normal menstrual cycles; nearly all patients develop irregular bleeding initially, which may persist for ≥ 6 months. 30

Timeline for Endometrial Restoration Post‑DMPA

After DMPA discontinuation, normal endometrial function typically recovers over 9–18 months, during which the lining gradually regains thickness and ovulatory cycles resume. 30

Consequences of Premature COC Discontinuation

Stopping combined oral contraceptives (COC) before completing the recommended active‑pill course does not resolve breakthrough bleeding, because the prolonged endometrial recovery from prior DMPA use continues regardless of the contraceptive method. 30

Immediate Evaluation and Management of Prolonged Breakthrough Bleeding on Combined Oral Contraceptives

Urgent Assessment (CDC MMWR Recommendations)

Assess for anemia promptly in patients presenting with light‑headedness, dizziness, and low energy after ≥ 3 months of continuous bleeding, as these symptoms strongly suggest significant blood loss. 31
Obtain hemoglobin/hematocrit immediately to quantify anemia severity. 32
Exclude pregnancy with a urine or serum β‑hCG test before any therapeutic change. 33
Screen for sexually transmitted infections (chlamydia, gonorrhea) via cervical testing. 31
Measure thyroid‑stimulating hormone to rule out thyroid dysfunction as a bleeding contributor. 32
Perform transvaginal ultrasound when clinically indicated to detect new uterine pathology such as polyps or fibroids. 33
Review medication list and adherence to identify possible drug interactions or missed doses that could precipitate breakthrough bleeding. 31

First‑Line Intervention (CDC MMWR Recommendations)

Initiate ibuprofen 400–600 mg orally three times daily for 5–7 days while the patient continues her current combined oral contraceptive (COC). This NSAID regimen reduces endometrial inflammation and often controls breakthrough bleeding. 32

Transition to a Monophasic Formulation (CDC MMWR Recommendations)

Complete the remaining tablets of the current triphasic COC before switching. 31
Begin the new monophasic COC (30–35 µg ethinyl estradiol with levonorgestrel or norgestimate) the day after the last tablet of the prior pack, without a hormone‑free interval. 32
Counsel that breakthrough bleeding may persist for 3–6 months after the switch but typically diminishes with continued use. 33

Management of Documented Anemia (American Academy of Family Physicians)

Start oral iron therapy (e.g., ferrous sulfate 325 mg daily or an equivalent dose) when hemoglobin is low. 34
Re‑measure hemoglobin 4–6 weeks after initiating iron to confirm hematologic recovery. 34

Second‑Line Options if NSAIDs Fail (CDC MMWR Recommendations)

Planned hormone‑free interval: Allow a 3–4‑day pill‑free break to induce withdrawal bleeding, only after the first 21 days of the new regimen and no more than once per month. 31
Additional estrogen: Add a short course (10–20 days) of low‑dose combined oral contraceptives or estrogen alone to reinforce endometrial stability. 32
Tranexamic acid: Give 1300 mg orally three times daily for 5 days during active bleeding episodes to promote hemostasis. 31

Counseling and Common Pitfalls (CDC MMWR Recommendations)

Reassure patients that breakthrough bleeding is common during the first 3–6 months of COC use and does not indicate method failure. 33
Advise against discontinuing the contraceptive without first offering therapeutic measures, as many women stop an effective method unnecessarily. 31
Emphasize the importance of evaluating anemia‑related symptoms (light‑headedness, dizziness, fatigue) with hemoglobin testing. 34
Instruct patients that hormone‑free intervals should not exceed one per month, because more frequent breaks reduce contraceptive efficacy. 32

Combined Oral Contraceptives with Ethinyl Estradiol and Norelgestromine for Heavy and Intermenstrual Bleeding

First‑Line Pharmacologic Therapy

The American Academy of Pediatrics recommends initiating a monophasic combined oral contraceptive containing 30–35 µg ethinyl estradiol with norelgestromine (or alternatives such as levonorgestrel or norgestimate) as the first‑line treatment for heavy menstrual and intermenstrual bleeding, because each tablet delivers a consistent hormone dose and promotes a thinner endometrium. 35

Management of Breakthrough Bleeding

The Centers for Disease Control and Prevention (CDC) notes that unscheduled intermenstrual bleeding is common during the first 3–6 months of combined oral contraceptive use and typically declines with continued therapy. 36
Before treating persistent breakthrough bleeding, a β‑hCG pregnancy test should be performed to exclude pregnancy. 36
First‑line for persistent breakthrough bleeding: a short course of non‑steroidal anti‑inflammatory drugs (e.g., mefenamic acid 500 mg three times daily or ibuprofen 400–600 mg three times daily) for 5–7 days while maintaining the combined oral contraceptive. 36
Second‑line option: a brief hormone‑free interval of 3–4 days to induce withdrawal bleeding; this interval must not be used within the first 21 days of therapy and should not exceed once per month to preserve contraceptive efficacy. 36
Third‑line strategy: a short course of additional estrogen‑containing hormones (10–20 days of combined oral contraceptive or estrogen alone) when NSAIDs are ineffective. 36

Extended‑Cycle Regimens

The American Academy of Pediatrics reports that extended or continuous regimens (active pills taken for 3–4 months followed by a 4–7‑day hormone‑free interval) are especially useful for managing heavy menstrual bleeding and anemia, although unscheduled intermenstrual bleeding is the most frequent adverse effect; this bleeding tends to decrease over time. 35

Additional Long‑Term Benefits

Use of combined oral contraceptives for more than three years provides protection against endometrial and ovarian cancers. 35
Long‑term use does not impair future fertility and is fully reversible after discontinuation. 35